ACRP CCRC Exam Prep Questions 2023/2024 GRADED A LATEST 2023
5 keer bekeken 0 keer verkocht
Vak
ACRP CCRC
Instelling
ACRP CCRC
ACRP CCRC Exam Prep Questions
2023/2024 GRADED A LATEST 2023
What are expected or possible consequences of over-estimation
of recruitment potential? - CORRECT ANSWER - The trial will
overrun its projected timeline
- The recruitment period will be prolonged and more sites may be
needed
- T...
ACRP CCRC Exam Prep Questions
2023/2024 GRADED A LATEST 2023
What are expected or possible consequences of over-estimation
of recruitment potential? - CORRECT ANSWER - The trial will
overrun its projected timeline
- The recruitment period will be prolonged and more sites may be
needed
- The study will not have sufficient data within the required
timeframe and will be stopped because of lack of budget
What should be the first consideration when conducting a clinical
trial? - CORRECT ANSWER Subject welfare
When is the investigator allowed to deviate from the protocol? -
CORRECT ANSWER When there is an immediate hazard to a
patient.
If the investigator wanted to deviate from the protocol for an
immediate hazard to a patient, according to ICH E6 guidelines
who world they need to report the deviation and rationale to, if
appropriate? - CORRECT ANSWER - The Sponsor
- IRB/IEC
- Regulatory Authorities
Which conditions should be fulfilled when enrolling a subject into
your trial? - CORRECT ANSWER - Subject meets all inclusion
criteria
- Subject has given written informed consent
You've been delegated to handle the storage and inventory of IP.
The study drug must be stored below 25C/77F. On a summer
Monday morning you discover that the temperature recording
machine in the storage room has failed so you doin't know what
,the temperature has been over the weekend. You check the
current temperature; it's 24C/75F. What should you do? -
CORRECT ANSWER - Contact the Sponsor, explain what
happened and ask for instructions
- Set up a site staff meeting to conduct a root cause analysis
A protocol amendment was issued for a trial. Your site received
IRB approval for the amendment and wants to implement the
increase in PO dose for your trial subjects as identified in the
amendment trial subjects. As delegated consenting duties you
must re-consent trial subjects before being able to administer the
adjusted dose. You decide to only re-consent trial subjects who
are still taking the IP and not from the subjects woh already
completed their drug intake period. Is this allowed according the
E6 Guideline for GCP? - CORRECT ANSWER No, these
subjects are still enrolled in the trial and therefore need to be
updated on any changes to the protocol.
A trial subject informs you she no longer wants to participant in
the trial. What should your course of action be? - CORRECT
ANSWER You ask if the patient wishes to share the reason why
she wants to leave the trial. If not, you exclude the subject from
the trial immediately.
A patient cannot recall the name of the heart condition medication
he took a few years ago. This is important information for deciding
whether the patient may be enrolled in a clinical trial (IC/EC).
What's your best course of action? - CORRECT ANSWER You
attempt to retrieve the patients medical history by contacting
previous caregivers and you wait for additional information before
enrollment.
Who has ultimate trial responsibility for each subject? -
CORRECT ANSWER The principle investigator.
,A trial subject suffers from severe repeat headaches. Should this
adverse event be reported to the IRB? - CORRECT ANSWER
No
What statements are true concerning an adverse drug reaction? -
CORRECT ANSWER - All noxious and unintended responses
to a medicinal product related to any dose should be considered
as an ADR
- An ADR suggests a relationship to trail medication
- All ADRs must be documented
What Adverse Events (AEs) are Serious Adverse Events (SAEs)?
- CORRECT ANSWER - Any AE that results in death
- Any AE that results in inpatient hospitalization
- Any AE that is a congenital anomaly
During a study visit a patient tells the investigator that she visited
an emergency room and received intensive treatment for allergic
bronchospasm. Since the patient was in the emergency room for
only three hours, the investigator did not assess the event as
serious. Is this a correct assessment? - CORRECT ANSWER
No, this would be a medically important event and should be
considered serious
What data points minimally need to be reported by the site when
reporting an SAE, so that the sponsor can process the event? -
CORRECT ANSWER Identification of event, product, and trial
subject
During a visit with investigator, a subject reported feeling heart
palpitations for a brief period of time during the previous evening.
The heart palpitations resolved without reoccurrence. The
investigator considered these symptoms to be unrelated to study
drug. The next day, the subject told a fellow student that he felt
tired and was planning on taking a nap. Later, the subject was
, found dead. A preliminary report from the medical examiner
indicated the subject died of pulmonary embolism. What should
your next course of action be? - CORRECT ANSWER - Record
these events in case report form
- Immediately notify sponsor about serious adverse events
When asked by a regulatory body why they received SAE related
information on 12/2013 from an incident that occurred in 5/2013,
the sponsor explained the reason being they received the trial
related SAE information from the investigator in 12/2013. Is the
sponsor correct in only holding the investigator accountable for
their late reporting? - CORRECT ANSWER No, the sponsor
should support the conduct QC activities with the sites to help
them ensure timely SAE reporting.
A trial subject in a cardiology trial is admitted to hospital with heart
attack. The investigator considers this event possibly related to
the study drug even though this is not listed in the IB as a
potential adverse reaction. What would the investigator report this
event to the sponsor as? - CORRECT ANSWER An
unexpected, serious adverse event
A 22y/o male was entered into a clinical study for treatment of
schizophrenia The study drug was administered orally, BID. One
week later, the subject visited the investigator complaining of
sever sore throat. The IB lists this as an occurrence reported by
1% of subjects receiving drug. How should this severe throat be
classified? - CORRECT ANSWER - An adverse event
- An adverse drug reaction
In regards to AE and ADR reporting, what statements are true? -
CORRECT ANSWER - All ADRs are AEs but not all AEs are
ADRs
- Worsening in pre-existing medical conditions is an AE
-Preplanned hospitalization is usually not an SAE
Voordelen van het kopen van samenvattingen bij Stuvia op een rij:
Verzekerd van kwaliteit door reviews
Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!
Snel en makkelijk kopen
Je betaalt supersnel en eenmalig met iDeal, creditcard of Stuvia-tegoed voor de samenvatting. Zonder lidmaatschap.
Focus op de essentie
Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!
Veelgestelde vragen
Wat krijg ik als ik dit document koop?
Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.
Tevredenheidsgarantie: hoe werkt dat?
Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.
Van wie koop ik deze samenvatting?
Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper GREATSTUDY. Stuvia faciliteert de betaling aan de verkoper.
Zit ik meteen vast aan een abonnement?
Nee, je koopt alleen deze samenvatting voor €12,16. Je zit daarna nergens aan vast.
